AbbVie (ABBV) Projected to Announce Quarterly Earnings on Friday

Key Points

• AbbVie is expected to report Q3 2026 results before the market opens on October 30. Analysts forecast earnings of $3.74 per share and revenue of $17.36 billion, compared with company guidance of $3.84–$3.88 per share.
• AbbVie’s latest quarter exceeded expectations, with EPS of $3.65 and revenue of $16.99 billion; revenue rose 10.2% year over year. The company also declared a quarterly dividend of $1.73, representing a 2.4% annualized yield.
• Pipeline news is mixed: lutikizumab met Phase 3 trial objectives for hidradenitis suppurativa, but analysts questioned the magnitude of its benefit and competitive positioning. AbbVie also halted an early-stage liver-cancer combination study.

AbbVie (NYSE:ABBV - Get Free Report) is expected to be posting its Q3 2026 results before the market opens on Friday, October 30th. Analysts expect the company to announce earnings of $3.74 per share and revenue of $17.36 billion for the quarter. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Individuals can find conference call details on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, October 30, 2026 at 9:00 AM ET.

AbbVie (NYSE:ABBV - Get Free Report) last posted its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The company had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter last year, the firm earned $2.97 earnings per share. The company's revenue was up 10.2% on a year-over-year basis. On average, analysts expect AbbVie to post $13.94 EPS for the current fiscal year and $16.06 EPS for the next fiscal year.

AbbVie Stock Performance

ABBV stock opened at $284.59 on Friday. The company's 50-day simple moving average is $265.60 and its 200 day simple moving average is $241.46. AbbVie has a 52 week low of $190.75 and a 52 week high of $291.40. The company has a market capitalization of $502.80 billion, a PE ratio of 26.20, a price-to-earnings-growth ratio of 1.30 and a beta of 0.24.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.4%. AbbVie's payout ratio is 195.48%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Lutikizumab met its Phase 3 INTREPID trial objectives. AbbVie reported that the experimental treatment for moderate-to-severe hidradenitis suppurativa achieved its primary HiSCR75 endpoint and eight ranked secondary endpoints, including reduced skin pain and fewer disease flares. The drug was generally well tolerated, with no new safety concerns. AbbVie INTREPID Phase 3 results
• Positive Sentiment: Investors continue to see potential in AbbVie’s broader immunology pipeline. Phase 2a results for a possible Skyrizi successor in Crohn’s disease and a promising eczema candidate could help support growth as AbbVie prepares for future patent expirations. Great News for AbbVie Stock Investors
• Neutral Sentiment: The INTREPID results were positive but commercially ambiguous. Although lutikizumab reduced abscess burden and met prespecified endpoints, the magnitude of benefit reportedly fell short of analyst benchmarks. That raises questions about the drug’s competitive positioning and potential sales opportunity, despite the successful trial. AbbVie skin disease drug Phase 3 results
• Negative Sentiment: Analysts characterized the efficacy as underwhelming. Lutikizumab beat placebo by roughly eight percentage points on its main measure, but the result lagged some efficacy benchmarks. Shares of rival MoonLake rose on expectations that its competing hidradenitis suppurativa therapy may remain better positioned. MoonLake reaction to AbbVie trial data
• Negative Sentiment: AbbVie halted an early-stage liver-cancer combination study. The discontinued Phase 1b trial removes one development program from the oncology pipeline, although its financial impact is likely limited compared with the company’s late-stage immunology portfolio. AbbVie liver cancer trial update

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company's stock, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is owned by insiders.

Analyst Ratings Changes

ABBV has been the topic of a number of analyst reports. Weiss Ratings upgraded shares of AbbVie from a "buy (b-)" rating to a "buy (b)" rating in a research report on Thursday, October 8th. Argus lifted their price target on shares of AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. Scotiabank boosted their price target on AbbVie from $280.00 to $320.00 and gave the company an "outperform" rating in a research note on Tuesday, October 6th. UBS Group increased their price target on AbbVie from $260.00 to $275.00 and gave the stock a "neutral" rating in a research report on Tuesday, October 6th. Finally, Bank of America restated a "buy" rating on shares of AbbVie in a research note on Tuesday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, AbbVie has an average rating of "Moderate Buy" and an average target price of $278.07.

AbbVie Company Profile

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.